Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Asso De Recherche Cancers Gynecologiques

Participant type

Pediatric, Patients

Age range

0-17 years, 18-64 years, 65+ years

Gender

Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

4 Aug 2021 → ongoing

Decision date (initial)

2024-10-01

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

External identifiers

EU CT number

2024-515310-40-01

EudraCT number

2020-002260-31

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

To estimate the complete response rate after perioperative treatment by chemotherapy and immunotherapy, using the RECIST 1.1

Secondary objectives 3

1. - To assess the safety profile of the combination immunotherapy and chemotherapy
2. - To assess Progression-Free Survival (PFS)
3. - To assess Overall Survival (OS)

Conditions and MedDRA coding

Patients with a confirmed diagnosis of ovarian small cell carcinoma.

Regulatory references

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. Patient who are at least 12 years of age on the day of signing informed consent with previously untreated, pathologically confirmed small cell carcinoma of the ovary. Patients could be included after one cycle of chemotherapy but have to start treatment within 4 weeks after the first cycle of chemotherapy. They will start the scheme at cycle 2.
2. Stage FIGO I to IV classification
3. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
4. Have adequate organ function: • Adequate marrow function  White blood cell (WBC) >2000/mm3 (stable off any growth factor within 4 weeks of first study drug administration)  Neutrophils >1500/ mm3 (stable off any growth factor within 4 weeks of first study drug administration)  Platelets > 100 × 103/mm3 (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration)  Haemoglobin > 9 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration) • Adequate other organ functions  ALT and AST < 3× institutional ULN  Total bilirubin < 1.5× institutional ULN (except Gilbert Syndrome: < 3.0 mg/dL)  Normal thyroid function, subclinical hypothyroidism (thyroid-stimulating hormone [TSH] < 10 mIU/mL) or have controlled hypothyroidism on appropriate thyroid supplementation  Left ventricular ejection fraction (LVEF) > 55 % measured by ECHO (preferred) or MUGA scans  Serum creatinine < 2× ULN or creatinine clearance (CrCl) > 60 mL/min (measured using the Cockcroft-Gault formula below):
5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial, prior to any study-specific procedure. The participant may also provide consent for Future Biomedical Research. However, participant may participate in the main trial without participating in Future Biomedical Research.
6. Covered by a medical insurance.
7. Stated willingness to comply with all study procedures and availability for the duration of the study.
8. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to treatment allocation.
9. For females of reproductive potential: use of highly effective contraception throughout the study period up to 120 days after the last dose of pembrolizumab and 180 days following the end of chemoradiotherapy (if applicable).

Exclusion criteria 19

1. Prior therapy for the disease with chemotherapy and/or an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
2. Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Inactivated rabies vaccines are allowed.
3. Patients who have had an allogenic tissue/solid organ transplant.
4. Patient who has received more than one cycle of platinum-based chemotherapy, or any prior systemic anti-cancer therapy including investigational agents for the SCCOHT. (Patients could be included after one cycle of platinum-based therapy).
5. Patients who have a known diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
6. Patients who have a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
7. Patients who have a contraindication to any component of cisplatin, adriamycine, vepeside and cyclophosphamide. Note: Investigators must use the local label for contraindications, prohibited medications, and precautions for use.
8. Patients who have severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients (refer to the IB for a list of excipients).
9. Patients who have a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and/or to any of their excipients (refer to the approved product label(s) for a list of excipients).
10. Patients who have an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
11. Patients who have a history of (non-infectious) pneumonitis/ interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease that requires steroids.
12. Has an active infection requiring systemic therapy.
13. Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
14. Has a history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
15. Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
17. Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.
18. Breastfeeding women.
19. Participation in another clinical study with an investigational product 30 days prior and during the treatment course, and 30 days after end of treatment.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Complete response rate is documented using RECIST 1.1

Secondary endpoints 2

1. Safety will be assessed using NCI CTC-AE v5
2. Efficacy will be documented using RECIST 1.1.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Auxiliary 4

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Asso De Recherche Cancers Gynecologiques

Sponsor organisation

Asso De Recherche Cancers Gynecologiques

Address

8 Rue Lamennais

City

Paris

Postcode

75008

Country

France

Scientific contact point

Organisation

Asso De Recherche Cancers Gynecologiques

Contact name

Patricia PAUTIER

Public contact point

Organisation

Asso De Recherche Cancers Gynecologiques

Contact name

Patricia PAUTIER

Locations

1 EU/EEA country · 13 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Application history

4 submissions — initial application plus substantial / non-substantial modifications